Saturday 17 October 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million. In the quarter to June 2026, revenue grew 1.62%, EPS grew 3.33%, free cash flow grew 2.68% and total debt fell 83.6%, each against the same quarter a year earlier.
4.82
0.53
−9.91%
Follow BIOA
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
— | — | 0.00 |
Altman Z-Score |
— | — | 10.98 |
P/S ratio |
— | — | 52.85 |
P/FCF ratio |
— | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | 12.64 |
P/Operating CF |
— | — | (16.83) |
P/B ratio |
— | — | 1.75 |
Price to Tangible BV |
— | — | 1.75 |
EV/Sales |
— | — | 22.01 |
EV/EBITDA |
— | — | 0.00 |
EV/Operating CF |
— | — | (2.43) |
EV/FCF |
— | — | (0.84) |
Quick Ratio |
0.43 | 12.76 | 14.00 |
Current Ratio |
0.44 | 12.86 | 14.24 |
Net Debt/EBITDA |
0.22 | 4.43 | 3.01 |
Debt/Assets |
54.78% | 2.37% | 0.90% |
Debt/Equity |
(0.08) | 0.03 | 0.01 |
Asset Turnover |
— | 0.00 | 0.03 |
Operating CF/Net income |
0.59 | 0.72 | 1.01 |
Capex/Depreciation |
(1.02) | (2.19) | (729.89) |
Interest Coverage |
(6.21) | (33.04) | (133.11) |
| 0.00% | (94.98%) | (27.09%) | |
| 0.00% | (37.02%) | (24.68%) | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
196.24% | (21.55%) | (30.12%) |
Average Days of Receivables |
— | — | 31.20 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 822.30% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 309.16% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 129.97% |
Graham Net Nets |
— | — | 0.56 |
Graham Number |
— | — | 0.00 |
Earnings Yield |
— | — | (16.93%) |
Free Cash Flow Yield |
— | — | (49.87%) |
Revenue per Share |
0.00 | 0.00 | 0.25 |
Operating CF per Share |
(22.33) | (4.80) | (2.27) |
Capex per Share |
(0.10) | (0.03) | (4.33) |
Free Cash Flow per Share |
(22.43) | (4.84) | (6.60) |
Cash per Share |
14.92 | 33.03 | 7.82 |
Shareholders Equity per Share |
(103.66) | 30.12 | 7.57 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(103.66) | 30.12 | 7.57 |
Free Cash Flow |
(37.53) | (51.89) | (237.09) |
Working Capital |
(32.86) | 329.33 | 266.66 |
Capital Expenditures |
(0.17) | (0.37) | (155.47) |
Net Current Asset Value |
(174.01) | 322.00 | 263.96 |
EV/EBIT |
— | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 17.28 |
Price to Operating Income |
— | — | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.50 | 0.28 | 0.22 |
Cash ROIC |
27.96% | (7.56%) | (42.66%) |
Accounts Receivable Turnover |
— | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
— | 1.93 | 2.34 |
Average Assets |
— | 192.08 | 326.56 |
Average Common Equity |
— | 74.87 | 297.59 |
Columns are period end dates